Misclassification of dysplasia in patients with inflammatory bowel disease: Consequences for progression rates to advanced neoplasia

Inflammatory Bowel Diseases

Volumn 17, Issue 5, 2011, Pages 1108-1116

  Van Schaik, Fiona D M ^a   Ten Kate, Fiebo J W ^a   Offerhaus, G Johan A ^a   Schipper, Marguerite E I ^a   Vleggaar, Frank P ^a   Van Der Woude, C Janneke ^b   Stokkers, Pieter C F ^c   De Jong, Dirk J ^e   Hommes, Daan W ^d   Van Bodegraven, Ad A ^f   Siersema, Peter D ^a   Oldenburg, Bas ^a,g  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NONE   (Netherlands)

Author keywords

colorectal cancer; dysplasia; inflammatory bowel disease

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DYSPLASIA; ENTERITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGIST; PRIORITY JOURNAL; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; CHILD; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CROHN DISEASE; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK FACTORS; YOUNG ADULT;

EID: 79953849266     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21467     Document Type: Article

References (23)

1. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
2. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
3. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105. (Pubitemid 47494461)
4. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G7-17. (Pubitemid 38802113)
5. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14: 931-968.
6. Bernstein CN, Shanahan F, Weinstein WM,. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994; 343: 71-74. (Pubitemid 24019346)
7. Befrits R, Ljung T, Jaramillo E, et al. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum. 2002; 45: 615-620. (Pubitemid 34507236)
8. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107: 934-944. (Pubitemid 24294554)
9. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669-676. (Pubitemid 44253749)
10. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125: 1311-1319. (Pubitemid 37409751)
11. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001; 194: 152-157. (Pubitemid 32519963)
12. Odze RD, Goldblum J, Noffsinger A, et al. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002; 15: 379-386. (Pubitemid 34326945)
13. van Diest PJ,. No consent should be needed for using leftover body material for scientific purposes. BMJ. 2002; 325: 648-651.
14. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4: 1346-1350. (Pubitemid 44716744)
15. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005; 54: 1573-1578. (Pubitemid 41531774)
16. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006; 130: 1941-1949. (Pubitemid 43816957)
17. Pekow JR, Hetzel JT, Rothe JA, et al. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 1352-1356.
18. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130: 1030-1038.
19. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6: 1225-1230.
20. Eaden JA, Mayberry JF,. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002; 51 (suppl 5): V10-V12. (Pubitemid 35222898)
21. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003; 124: 544-560. (Pubitemid 36169269)
22. Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003; 52: 1127-1132. (Pubitemid 36877424)
23. Thomas T, Nair P, Dronfield MW, et al. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005; 17: 1317-1324. (Pubitemid 41830452)